US OptionsDetailed Quotes
XBI241213C101500
- 0.01
- -0.04-80.00%
15min DelayTrading Dec 12 10:30 ET
0.01High0.01Low
0.01Open0.05Pre Close1 Volume168 Open Interest101.50Strike Price1.00Turnover59.25%IV7.49%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0101Delta0.0092Gamma9444.01Leverage Ratio-0.0100Theta0.0000Rho95.65Eff Leverage0.0013Vega
SPDR S&P Biotech ETF Stock Discussion
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...
» Is this a smid-cap biopharma buying opportunity? 🤔
Stock market sell-off, e.g., $NASDAQ, started late last week on weak jobs data
XBI/smid-cap biopharma were part of sell-off
But..
» Is this sell-off justified for smid-cap biopharma?
» Is this a buying opportunity for smid-cap biopharma?
💡 Lower economic/jobs data = more likely entering lowering interest rate cycle for Fed Reserve
Usually go...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
It does not follow the XBI and Russell 2000 up trend for this period of time. Meaning market drops, it drops. Market ups, it still drop. Gonna cut off from my side
$Merck & Co (MRK.US)$ already has an active partnership with $Janux Therapeutics (JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF (XBI.US)$ in which $Merck & Co (MRK.US)$ already has a seat at the table.
$Merck & Co (MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
$Bristol-Myers Squibb (BMY.US)$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb (BMY.US)$
Despite recent performance s...
No comment yet